Mydecine Innovations Group Inc (OTCMKTS: MYCOF) is back in the news. The corporate house announced that it would support the research initiative of Dr. Matthew Johnson.
Information about the research study
Mydecine Innovations Group Inc has announced that the group will supply MYCO-001, one of its leading drug candidates. The same will be used in a smoking cessation study which will be performed at multiple locations. Johns Hopkins University (JHU), New York University, and the University of Alabama Birmingham are research locations. The research study is spearheaded by Dr. Matthew Johnson, who is regarded as one of the leading researchers who works in areas of drug and substance use. The lead researcher, Dr. Johnson, has received funding for the study. Besides this, the National Institute on Drug Abuse (NIDA) has sanctioned the grant. According to reports, for the first time in five decades, the Government of the U.S. has approved funds for a research study involving a psychedelic compound for therapeutic purposes.
Mydecine Innovations Group Inc has inked a five-year research agreement with Johns Hopkins University (JHU)
Mydecine Innovations Group Inc has inked a five-year research agreement with Johns Hopkins University (JHU). Under the agreement, the two will study psychedelics’ impact on smoking cessation, among other initiatives. In addition, the group in September this year made it official that it has joined hands with Dr. Johnson. The two have partnered to complete a clinical trial for smoking cessation, which involves MYCO-001. If all falls in place, we can expect the launch of the clinical trial during 1Q 2022. It is learned that both the clinical practice and the current multi-state study will run parallel. The management at Mydecine Innovations Group Inc is confident that results from both the studies will help the group to determine the efficacy of MYCO-001. In addition, the study results will help the group learn how the potential drug candidate can be used in the future.
Mydecine Innovations Group Inc has made advancements in clinical trials involving MYCO-001
Mydecine Innovations Group Inc, Josh Bartch, said that the group is happy to support Dr. Johnson and his research team. The CEO added that the group had made tremendous advancements in MYCO-001 clinical trials.
CV Sciences Inc. (OTCMKTS: CVSI) Reports 8% Drop In Sales In Q3 2021 Attributable To Regulatory Uncertainty in CBD
Post Views: 7 CV Sciences Inc. (OTCMKTS: CVSI) has announced its third-quarter 2021 financial results for the period ending September...
AuxlyCannabis Group Inc. (OTCMKTS: CBWTF) Reports Net Revenue Growth 95% In Q3 2021
Post Views: 45 Auxly Cannabis Group Inc. (OTCMKTS: CBWTF) has announced its financial results for the third quarter and nine...
Vivo Cannabis Inc. (OTCMKTS: VVCIF) Releases Q3 2021 Net Revenue of $6.2 Million as It Expands Internationally
Post Views: 31 Vivo Cannabis Inc. (OTCMKTS: VVCIF) has released its Q3 2021 operating and financial results for the quarter...
Rubicon Organics Inc. (OTCMKTS: ROMJF) Announces 124% YoY Growth In Revenue in Q3 2021 After Launching New Brands
Post Views: 11 Rubicon Organics Inc. (OTCMKTS: ROMJF) has released its Q3 2021 results ending September 30, 2021, in which...
Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) Reports 120% Sequential Revenue Growth in Q3 2021
Post Views: 14 Sugarbud Craft Growers Corp (OTCMKTS: SBUDF) has filed its unaudited consolidated preliminary financial statements for the quarter...
Indiva Limited (OTCMKTS: NDAF) Reports 143% YoY increase in Revenue In Q3 2021
Post Views: 46 Indiva Limited (OTCMKTS: NDAF) has announced its operating and financial results for the third quarter ending September...